The U.S. Food and Drug Administration (FDA) had conducted an inspection at the injectable facility of Eugia SEZ Pvt. Ltd. (a 100% step-down subsidiary of Aurobindo Pharma Ltd.), situated at Polepally Village, Jadcherla Mandal, Mahaboobnagar District, Telangana, from February 19 to February 29, 2024.

The Unit has now received Establishment Inspection Report classifying the facility as "Voluntary Action Indicated" (VAI).